254 related articles for article (PubMed ID: 23037910)
1. Adverse periocular reactions to five types of prostaglandin analogs.
Inoue K; Shiokawa M; Higa R; Sugahara M; Soga T; Wakakura M; Tomita G
Eye (Lond); 2012 Nov; 26(11):1465-72. PubMed ID: 23037910
[TBL] [Abstract][Full Text] [Related]
2. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.
Inoue K; Shiokawa M; Wakakura M; Tomita G
J Glaucoma; 2013; 22(8):626-31. PubMed ID: 22936280
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.
Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC
Curr Eye Res; 2007 Dec; 32(12):1037-43. PubMed ID: 18085467
[TBL] [Abstract][Full Text] [Related]
4. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
Li N; Chen XM; Zhou Y; Wei ML; Yao X
Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
[TBL] [Abstract][Full Text] [Related]
6. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans.
Herndon LW; Robert D Williams ; Wand M; Asrani S
Am J Ophthalmol; 2003 May; 135(5):713-5. PubMed ID: 12719085
[TBL] [Abstract][Full Text] [Related]
7. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial.
Arcieri ES; Santana A; Rocha FN; Guapo GL; Costa VP
Arch Ophthalmol; 2005 Feb; 123(2):186-92. PubMed ID: 15710814
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
Kucukevcilioglu M; Bayer A; Uysal Y; Altinsoy HI
Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
[TBL] [Abstract][Full Text] [Related]
9. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
10. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
Parrish RK; Palmberg P; Sheu WP;
Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma.
Faridi UA; Saleh TA; Ewings P; Venkateswaran M; Cadman DH; Samarasinghe RA; Vodden J; Claridge KG
Clin Exp Ophthalmol; 2010 Oct; 38(7):678-82. PubMed ID: 20456437
[TBL] [Abstract][Full Text] [Related]
12. Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits.
Giannico AT; Lima L; Russ HH; Montiani-Ferreira F
J Ocul Pharmacol Ther; 2013 Nov; 29(9):817-20. PubMed ID: 23981234
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin analog treatment of glaucoma and ocular hypertension.
Alexander CL; Miller SJ; Abel SR
Ann Pharmacother; 2002 Mar; 36(3):504-11. PubMed ID: 11895065
[TBL] [Abstract][Full Text] [Related]
14. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost.
Nakakura S; Tabuchi H; Kiuchi Y
Optom Vis Sci; 2011 Sep; 88(9):1140-4. PubMed ID: 21666524
[TBL] [Abstract][Full Text] [Related]
15. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
McCarey BE; Kapik BM; Kane FE;
Ophthalmology; 2004 Aug; 111(8):1480-8. PubMed ID: 15288975
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study.
Kammer JA; Katzman B; Ackerman SL; Hollander DA
Br J Ophthalmol; 2010 Jan; 94(1):74-9. PubMed ID: 19726422
[TBL] [Abstract][Full Text] [Related]
17. In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.
Choi HY; Lee JE; Lee JW; Park HJ; Lee JE; Jung JH
J Ocul Pharmacol Ther; 2012 Apr; 28(2):146-52. PubMed ID: 22107041
[TBL] [Abstract][Full Text] [Related]
18. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.
Park J; Cho HK; Moon JI
Jpn J Ophthalmol; 2011 Jan; 55(1):22-7. PubMed ID: 21331688
[TBL] [Abstract][Full Text] [Related]
19. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials.
Honrubia F; García-Sánchez J; Polo V; de la Casa JM; Soto J
Br J Ophthalmol; 2009 Mar; 93(3):316-21. PubMed ID: 19019922
[TBL] [Abstract][Full Text] [Related]
20. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost.
Aihara M; Shirato S; Sakata R
Jpn J Ophthalmol; 2011 Nov; 55(6):600-4. PubMed ID: 21953485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
